Table 1 Baseline characteristics of the study population
Professional Collaborative Team (n = 61) | Medical Oncologists (n = 61) | Total | p-value | |
|---|---|---|---|---|
n (%) | n (%) | n(%) | ||
Gender | 0.846 | |||
Male | 42 (68.85) | 41 (67.21) | 83 (68.03) | |
Female | 19 (31.15) | 20 (32.79) | 39 (31.97) | |
Age | ||||
Median (Min—Max) | 63 (20—88) | 59 (22—81) | 0.862‡ | |
date admit | ||||
Median (Min—Max) | 14 (7—127) | 11 (7—45) | 0.012‡ | |
Type of Cancer | ||||
Primary Lung Cancer | 14 (22.95) | 21 (34.43) | 35 (28.68) | 0.161 |
Hepatocellular Carcinoma | 11 (18.03) | 3 (4.92) | 14 (11.47) | 0.023 |
Esophagus/Gastric/billiary tract cancer | 11 (18.03) | 12 (19.67) | 23 (18.85) | 0.817 |
Head and Neck Cancer | 4 (6.56) | 9 (14.75) | 13 (10.65) | 0.142 |
Colon Cancer | 4 (6.56) | 6 (9.84) | 10 (8.19) | 0.509 |
Genitourinary Cancer | 6 (9.84) | 2 (3.28) | 8 (4.91) | 0.272† |
Breast Cancer | 4 (6.56) | 4 (6.56) | 8 (6.55) | 1.000 |
Musculoskeletal Cancer | 4 (6.56) | 1 (1.64) | 5 (4.09) | 0.365† |
Two primary cancer | 2 (3.28) | 2 (3.28) | 4 (3.27) | 1.000 |
Gynecologic Cancer | 1 (1.64) | 1 (1.64) | 2 (1.63) | 1.000† |
Brain Metastasis at Admission | 6 (9.84) | 9 (14.75) | 15 (12.29) | 0.408 |
Liver Metastasis at Admission | 27 (44.26) | 13 (21.31) | 40 (32.78) | 0.007 |
Type of Treatment | ||||
Chemotherapy | 38 (62.30) | 38 (62.30) | 76 (62.3) | 1.000 |
Surgery | 19 (31.15) | 18 (29.51) | 37 (30.3) | 0.844 |
Immunotherapy/Targeted | 7 (11.48) | 10 (16.39) | 17 (13.4) | 0.433 |
Hormonal therapy | 5 (8.20) | 1 (1.64) | 6 (4.9) | 0.207† |
Type of Problems | ||||
Pain | 45 (73.77) | 26 (43.33) | 71 (58.19) | 0.001 |
Dyspnea | 21 (34.43) | 29 (47.54) | 50 (40.98) | 0.141 |
Fatigue | 23 (37.70) | 16 (26.23) | 39 (31.96) | 0.174 |
Abdominal Pain | 25 (40.98) | 17 (27.87) | 42 (34.42) | 0.127 |
Nausea | 7 (11.48) | 12 (19.67) | 19 (15.57) | 0.212 |
Bedsore | 1 (1.64) | - | 1 (0.8) | 1.000† |